Truncated growth hormone-releasing hormone analog comprising the first 29 of 44 amino acids of native GHRH while retaining full receptor binding activity. Sermorelin was the first FDA-approved GH secretagogue (for pediatric GH deficiency, discontinued 2008) and preserves physiological GH pulsatility by working through the endogenous GHRH receptor on anterior pituitary somatotrophs.
Research Profile
Structure29 amino acids, ~3,358 Da
TargetsGHRH receptor on pituitary somatotrophs
Research FocusPhysiological GH pulsatility restoration, age-related GH decline
ReconstitutionBacteriostatic water — 1 mg/mL
Stability14 days at 2–8°C
Key distinction: Truncated GHRH analog retaining full GHRH-R binding in only 29 of 44 amino acids — the historical benchmark for all subsequent GHRH analogs.
Scientific Evidence
Published Research
[1]
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006;1:307-314 — PubMed 18046886
Research Use Only. All products sold by Lumen Peppers are intended solely for in vitro research and laboratory purposes. They are not drugs, supplements, or foods. Nothing on this page constitutes medical advice. Researchers are responsible for compliance with all applicable regulations. Last updated: April 14, 2026.